TScan Therapeutics 대차 대조표 상태
재무 상태 기준 확인 5/6
TScan Therapeutics has a total shareholder equity of $255.2M and total debt of $30.4M, which brings its debt-to-equity ratio to 11.9%. Its total assets and total liabilities are $374.9M and $119.7M respectively.
주요 정보
11.9%
부채 비율
US$30.45m
부채
| 이자 보상 비율 | n/a |
| 현금 | US$297.68m |
| 주식 | US$255.22m |
| 총 부채 | US$119.65m |
| 총 자산 | US$374.87m |
최근 재무 상태 업데이트
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17
Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18Recent updates
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
Aug 26Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target
Mar 11TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Aug 10TScan Therapeutics appoints Debora Barton as Chief Medical Officer
Jul 07Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18재무 상태 분석
단기부채: TCRX's short term assets ($299.5M) exceed its short term liabilities ($38.6M).
장기 부채: TCRX's short term assets ($299.5M) exceed its long term liabilities ($81.1M).
부채 대 자본 내역 및 분석
부채 수준: TCRX has more cash than its total debt.
부채 감소: Insufficient data to determine if TCRX's debt to equity ratio has reduced over the past 5 years.
대차 대조표
현금 런웨이 분석
과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.
안정적인 현금 활주로: TCRX has sufficient cash runway for more than 3 years based on its current free cash flow.
예측 현금 활주로: TCRX has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 27.4% each year.